Episode 53: CAR-T Therapies

What if cancer treatment wasn’t a drug but a living, evolving system inside your body?

In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from treating disease to programming the immune system.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#CAR-T #CellTherapy #Biotech #Oncology #Immunotherapy #CRISPR #HealthcareInnovation #Pharma #BiotechPodcast #PetriDishPerspectives #PrecisionMedicine #CancerResearch #FutureOfMedicine

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

I want you to imagine this.

A patient walks into a hospital with late-stage leukemia. They’ve failed chemotherapy. They’ve relapsed after a bone marrow transplant. By every conventional metric, they are out of options.

And then something radical happens.

Doctors take out their immune cells… reprogram them in a lab… and put them back in.

Weeks later, the cancer is gone. This is CAR-T therapy—one of the most important breakthroughs in modern medicine. A living drug. A programmable immune system. A therapy that doesn’t just treat disease—but hunts it.

Today, we’re diving into the full story of CAR-T: the science, the people, the companies, the billions of dollars, and the massive unsolved challenges that still define this field.

Because CAR-T isn’t just a therapy.

It’s a new operating system for medicine.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Concept: Turning T Cells into Guided Missiles

At its core, CAR-T is deceptively simple.

Your immune system already has T cells—cells designed to find and kill infected or abnormal cells. But cancer is clever. It hides. It suppresses immune responses. It evolves.

So scientists asked a simple but powerful question:

What if we could reprogram T cells to recognize cancer directly?

That’s what a Chimeric Antigen Receptor, or CAR, does.

It’s a synthetic receptor engineered onto a T cell. And it has four key components:

• An antibody-derived domain that recognizes a specific target on cancer cells
• A structural hinge and membrane anchor
• A signaling domain that activates the T cell
• And a co-stimulatory domain that amplifies the immune response

The result?

A T cell that no longer needs to “guess” what’s dangerous. It’s been explicitly programmed.

It sees the target. It activates. It kills.

And unlike traditional drugs, it doesn’t just act once. It expands. It persists. It becomes a living, evolving therapy inside the patient.

The Origins: Academic Curiosity in the 1980s

The roots of CAR-T go back to the late 1980s with Zelig Eshhar at the Weizmann Institute of Science.

Eshhar had an idea that sounded almost absurd at the time: take the specificity of antibodies and graft it onto T cells. He created the first chimeric antigen receptors—early versions of CARs. A chimeric antigen receptor (CAR) is a laboratory-engineered protein that combines antigen-binding, antibody-like specificity with T-cell activating functions, commonly used to program immune cells to kill cancer.

And technically… they worked. But clinically? They failed.

These first-generation CAR-T cells lacked persistence. They didn’t expand well. They didn’t survive long enough in the body to make a meaningful impact.

For years, the concept sat in the shadows. Interesting. Elegant. But not viable.

Everything changed in the early 2000s.

Scientists realized that T cells don’t just need activation—they need reinforcement.

Enter co-stimulatory domains.

Two major camps emerged:

• CD28 → faster, more aggressive activation
• 4-1BB → slower but longer-lasting persistence

This was the missing piece.

And leading this transformation were pioneers like Carl June at University of Pennsylvania and Michel Sadelain at Memorial Sloan Kettering Cancer Center.

They didn’t just improve CAR-T. They made it real.

In the early 2010s, something happened that changed the trajectory of oncology.

Patients with advanced leukemia—who had exhausted all treatment options—were given CAR-T therapy.

And the results were… shocking. Complete remissions. In patients expected to die within months. Tumor burdens collapsing in weeks. These weren’t incremental improvements. These were step-function changes.

For the first time, the idea of a “living drug” wasn’t theoretical. It was clinical reality.

The Business Explosion: Billions Flow In

Then came 2017—the year CAR-T officially entered the pharmaceutical industry.

The first approval:

• Kymriah from Novartis

Developed by Novartis, Kymriah became the first FDA-approved CAR-T therapy in 2017, marking the transition of cell therapy from experimental to commercial reality.

• Target: CD19
• Indications: Pediatric/young adult B-cell ALL; later expanded to DLBCL
• Co-stimulatory domain: 4-1BB (drives longer persistence)

Kymriah’s significance is less about dominance today and more about proof of concept. It validated that genetically engineered T cells could induce durable remissions in aggressive blood cancers. However, commercially, it has lagged behind competitors due to manufacturing complexity and slower uptake in adult lymphoma.

Shortly after:

• Yescarta from Kite Pharma, acquired by Gilead Sciences

Developed by Kite Pharma (acquired by Gilead Sciences), Yescarta quickly became a market leader in aggressive lymphomas.

• Target: CD19
• Indications: Large B-cell lymphomas (including DLBCL)
• Co-stimulatory domain: CD28 (faster, more aggressive activation)

Yescarta is known for rapid tumor killing and strong response rates, especially in earlier-line settings. It helped establish CAR-T as a standard of care in relapsed/refractory lymphoma, though with a tradeoff of higher rates of CRS and neurotoxicity compared to 4-1BB-based therapies.

This was the inflection point.

CAR-T moved from academic labs to billion-dollar balance sheets.

And suddenly, everyone wanted in.

The deals came fast—and big.

In 2017, Gilead Sciences acquired Kite Pharma for nearly $12 billion.

In 2019, Bristol Myers Squibb acquired Celgene for $74 billion—bringing CAR-T assets into its portfolio.

Then came:

• Breyanzi

From Bristol Myers Squibb, Breyanzi was designed with manufacturing control and safety optimization in mind.

• Target: CD19
• Indications: Large B-cell lymphomas
• Unique feature: Defined CD4/CD8 T-cell composition

Breyanzi’s key differentiator is its controlled cell composition, which leads to more predictable safety profiles, particularly lower severe CRS and neurotoxicity rates. Clinically, it’s often positioned as a “safer” CAR-T option while maintaining strong efficacy.

• Abecma

Also from Bristol Myers Squibb (via Celgene), Abecma was the first CAR-T approved for multiple myeloma.

• Target: BCMA (B-cell maturation antigen)
• Indication: Relapsed/refractory multiple myeloma

Abecma expanded CAR-T beyond CD19 into plasma cell malignancies, opening a massive new market. While effective, durability of response has been somewhat variable, highlighting antigen escape and disease complexity in myeloma.

• Carvykti from Johnson & Johnson and Legend Biotech

Developed by Johnson & Johnson and Legend Biotech, Carvykti is widely seen as the best-in-class CAR-T for multiple myeloma.

• Target: BCMA
• Indication: Relapsed/refractory multiple myeloma
• Key feature: Dual-epitope binding design

Carvykti delivers exceptionally deep and durable responses, with very high complete remission rates. However, it comes with unique neurotoxicity risks (including delayed effects) and significant manufacturing bottlenecks, limiting supply.

The pattern was clear:

Biotech innovates → Big Pharma scales.

Why CAR-T Works So Well in Blood Cancers

CAR-T has been most successful in hematologic cancers.

Why?

Three reasons:

1. Clean targets like CD19 and BCMA
2. Accessibility—blood cancers circulate
3. Less hostile environment than solid tumors

In this setting, CAR-T thrives.

It finds its target easily. Expands rapidly. And eliminates disease at scale.

The Dark Side: Toxicity and Bottleneck

But CAR-T isn’t without danger.

The same immune activation that kills cancer can overwhelm the body.

Two major toxicities define the field:

• Cytokine Release Syndrome (CRS)
• Neurotoxicity (ICANS)

Patients can experience high fevers, organ dysfunction, even neurological symptoms.

Managing these risks has become a core competency in CAR-T treatment centers.

Here’s the part most people don’t see.

CAR-T is not just biology. It’s logistics.

Each treatment is custom-made.

• Cells collected from the patient
• Engineered in a lab
• Expanded
• Shipped back
• Infused

This process takes weeks.

Costs hundreds of thousands of dollars.

And is incredibly difficult to scale.

Which brings us to the next evolution.

The Next Frontier: Off-the-Shelf CAR-T

What if you didn’t need to use the patient’s own cells?

What if CAR-T could be manufactured in bulk?

That’s the promise of allogeneic CAR-T.

Companies like:

• Allogene Therapeutics

Allogene is a clinical-stage biotech focused on solving the biggest bottleneck in CAR-T: manufacturing and scalability. Instead of using a patient’s own cells (autologous CAR-T), they develop allogeneic CAR-T (“AlloCAR-T”) therapies derived from healthy donors. The company was co-founded by Arie Belldegrun, M.D. (Executive Chairman) and David Chang, M.D., Ph.D. (President and CEO), previously built Kite Pharma, which was acquired by Gilead Sciences in 2017.

• Core thesis: Turn CAR-T into a mass-producible biologic, not a bespoke therapy
• Key advantage:
  • On-demand availability (no weeks-long manufacturing delay)
  • Lower cost potential
  • Scalable production (tens of thousands of doses/year target)
• Pipeline focus: Blood cancers, solid tumors, and increasingly autoimmune diseases

Strategic positioning: Allogene is essentially trying to do for CAR-T what monoclonal antibodies did for biologics—standardize, industrialize, and scale it globally. The risk remains biology: immune rejection and durability.

• CRISPR Therapeutics

CRISPR Therapeutics, co-founded by Nobel prize winner, Dr. Emmanuelle Charpentier, is one of the leading companies translating CRISPR/Cas9 gene editing into human therapeutics—arguably one of the most transformative technologies in modern biology.

• Core platform: CRISPR/Cas9 → precise editing of DNA
• Therapeutic areas:
  • Hemoglobinopathies (e.g., sickle cell disease)
  • Oncology (including CAR-T via gene editing)
  • Regenerative medicine

Strategic edge: They’re not just building drugs—they’re building a programmable genome engineering platform.

In CAR-T context: CRISPR is critical for:

• Creating allogeneic (“universal”) CAR-T cells
• Knocking out immune markers to avoid rejection
• Engineering more potent, durable cell therapies

Big picture: CRISPR Therapeutics sits upstream of many next-gen therapies—it’s a tools + therapeutics hybrid, similar to how NVIDIA sits upstream in AI.

• Caribou Biosciences

Caribou is a CRISPR pioneer company founded on foundational work from Jennifer Doudna’s lab at UC Berkeley.

• Core focus: CRISPR genome engineering, particularly next-gen cell therapies
• Flagship approach:
  • Precision-edited allogeneic CAR-T cells
  • Multiplex editing (editing multiple genes simultaneously)

Key differentiator: Caribou emphasizes precision and multiplex editing—engineering cells that are:

• More durable
• Less immunogenic
• More controllable

Strategic positioning: If Allogene is solving scale, Caribou is solving cell engineering sophistication. They’re building “smarter” cell therapies, not just more scalable ones.

These companies are all working to create universal donor cells.

The goal:

• Lower cost
• Faster treatment
• Scalable manufacturing

But the challenge is immune rejection and graft-versus-host disease.

Still unsolved. But progress is real.

The Biggest Challenge: Solid Tumors

This is the elephant in the room.

CAR-T dominates blood cancers.

But struggles in solid tumors.

Why?

• Tumor heterogeneity
• Immunosuppressive microenvironment
• Poor cell trafficking
• Antigen escape

This is where the next decade of innovation will happen.

Lessons from CAR-T

If you zoom out, CAR-T teaches us something bigger about biotech:

1. Platforms beat products
 CAR-T is not one drug—it’s a category.

2. Convergence drives breakthroughs
 Immunology + gene editing + manufacturing = success

3. Academia still leads innovation
 Industry scales it—but academia starts it.

4. Manufacturing is strategy
 The winners will solve cost and scale—not just biology.

What’s next for CAR-T?

The field is already evolving.

• CAR-NK cells
• CAR-macrophages
• In vivo CAR engineering
• AI-designed receptors
• Combination therapies

We are moving from:

Cell therapy → Programmable biology

Outro: The Beginning of Programmable Medicine

CAR-T is still early.

It feels mature because it works.

But in reality, we’re just getting started.

We’ve proven we can reprogram immune cells.

Now the question is:

What else can we reprogram?

This is no longer about cancer alone.

This is about rewriting biology itself.

And if CAR-T is the first chapter…

Then programmable medicine is the book.

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening. See you next Thursday. Good bye.

References

1. www.wikipedia.org
2. https://www.fiercebiotech.com/ 
3. https://finance.yahoo.com/ 
4. https://endpoints.news/